308 related articles for article (PubMed ID: 19589050)
21. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.
Binder EB; Salyakina D; Lichtner P; Wochnik GM; Ising M; Pütz B; Papiol S; Seaman S; Lucae S; Kohli MA; Nickel T; Künzel HE; Fuchs B; Majer M; Pfennig A; Kern N; Brunner J; Modell S; Baghai T; Deiml T; Zill P; Bondy B; Rupprecht R; Messer T; Köhnlein O; Dabitz H; Brückl T; Müller N; Pfister H; Lieb R; Mueller JC; Lõhmussaar E; Strom TM; Bettecken T; Meitinger T; Uhr M; Rein T; Holsboer F; Muller-Myhsok B
Nat Genet; 2004 Dec; 36(12):1319-25. PubMed ID: 15565110
[TBL] [Abstract][Full Text] [Related]
22. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects.
Künzel HE; Zobel AW; Nickel T; Ackl N; Uhr M; Sonntag A; Ising M; Holsboer F
J Psychiatr Res; 2003; 37(6):525-33. PubMed ID: 14563384
[TBL] [Abstract][Full Text] [Related]
23. Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation.
Reppermund S; Zihl J; Lucae S; Horstmann S; Kloiber S; Holsboer F; Ising M
Biol Psychiatry; 2007 Sep; 62(5):400-6. PubMed ID: 17188252
[TBL] [Abstract][Full Text] [Related]
24. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety.
Ising M; Holsboer F
Exp Clin Psychopharmacol; 2007 Dec; 15(6):519-28. PubMed ID: 18179304
[TBL] [Abstract][Full Text] [Related]
25. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
[TBL] [Abstract][Full Text] [Related]
26. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression.
Kunugi H; Hori H; Adachi N; Numakawa T
Psychiatry Clin Neurosci; 2010 Oct; 64(5):447-59. PubMed ID: 20923424
[TBL] [Abstract][Full Text] [Related]
27. Use of endocrine hormones for treating depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Dec; 48(12):13-6. PubMed ID: 21117521
[TBL] [Abstract][Full Text] [Related]
28. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis.
Lombardo G; Enache D; Gianotti L; Schatzberg AF; Young AH; Pariante CM; Mondelli V
Psychoneuroendocrinology; 2019 Dec; 110():104420. PubMed ID: 31499391
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activity.
Adli M; Bschor T; Bauer M; Lucka C; Lewitzka U; Ising M; Uhr M; Mueller-Oerlinghausen B; Baethge C
Neuropsychobiology; 2009; 60(1):23-30. PubMed ID: 19684420
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits.
Maric NP; Adzic M
Psychiatr Danub; 2013 Sep; 25(3):299-305. PubMed ID: 24048401
[TBL] [Abstract][Full Text] [Related]
31. CRH signaling. Molecular specificity for drug targeting in the CNS.
Refojo D; Holsboer F
Ann N Y Acad Sci; 2009 Oct; 1179():106-19. PubMed ID: 19906235
[TBL] [Abstract][Full Text] [Related]
32. Antiglucocorticoid therapies in major depression: a review.
Murphy BE
Psychoneuroendocrinology; 1997; 22 Suppl 1():S125-32. PubMed ID: 9264159
[TBL] [Abstract][Full Text] [Related]
33. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.
Holsboer F
J Psychiatr Res; 1999; 33(3):181-214. PubMed ID: 10367986
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project.
Hennings JM; Owashi T; Binder EB; Horstmann S; Menke A; Kloiber S; Dose T; Wollweber B; Spieler D; Messer T; Lutz R; Künzel H; Bierner T; Pollmächer T; Pfister H; Nickel T; Sonntag A; Uhr M; Ising M; Holsboer F; Lucae S
J Psychiatr Res; 2009 Jan; 43(3):215-29. PubMed ID: 18586274
[TBL] [Abstract][Full Text] [Related]
35. [New developments in pharmacotherapy of depression].
Rupprecht R; Baghai TC; Möller HJ
Nervenarzt; 2004 Mar; 75(3):273-80. PubMed ID: 15021929
[TBL] [Abstract][Full Text] [Related]
36. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?
Barden N; Reul JM; Holsboer F
Trends Neurosci; 1995 Jan; 18(1):6-11. PubMed ID: 7535490
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response.
Heydendael W; Jacobson L
Brain Res; 2008 Oct; 1238():93-107. PubMed ID: 18761333
[TBL] [Abstract][Full Text] [Related]
38. [Neurobiological mechanisms of depression and antidepressant therapy].
Shishkina GT; Dygalo NN
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(2):138-52. PubMed ID: 20469588
[TBL] [Abstract][Full Text] [Related]
39. Mouse mutants for the study of corticotropin-releasing hormone receptor function: development of novel treatment strategies for mood disorders.
Keck ME; Holsboer F; Müller MB
Ann N Y Acad Sci; 2004 Jun; 1018():445-57. PubMed ID: 15240401
[TBL] [Abstract][Full Text] [Related]
40. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
